Product Description
Mechanisms of Action:
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Acer Therapeutics Inc.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hot Flashes|Menopause
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05325775 |
ACER-801-201 | P2 |
Completed |
Hot Flashes|Menopause |
2023-03-04 |
50% |
2023-04-05 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/01/2024 |
PubMed |
Systematic review of neurokinin-3 receptor antagonists for the management of vasomotor symptoms of menopause. |
|
11/01/2023 |
PubMed |
Activation of neurokinin-III receptors modulates human atrial TASK-1 currents. |
|
05/01/2023 |
News Article |
Acer Therapeutics Announces OLPRUVA™ Commercial Launch Progressing Ahead of Schedule |
|
03/22/2023 |
News Article |
Acer Therapeutics Announces Data Presented at Society for Inherited Metabolic Disorders Annual Meeting Identifying Preferred Urea Cycle Disorder Treatment Attributes |
|
03/22/2023 |
News Article |
Acer Therapeutics Announces $2.675 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules |
|
03/17/2023 |
News Article |
Acer Therapeutics Announces Topline Results from ACER-801 (Osanetant) Phase 2a Trial |
|
06/11/2022 |
PubMed |
Nk3R blockade has sex-divergent effects on memory in mice. |